Evidence map›Paper›PMID 36927977›Full record

ArticleBritish journal of cancer2023

Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.

Lucy X Ma, Yifan Wang, Osvaldo Espin-Garcia, Michael J Allen, Gun Ho Jang, Amy Zhang, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe and 13 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02750657 (Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas), which is not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02750657 completednot on this map

Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study

TypeobservationalSponsorUniversity Health Network, TorontoRan2015 to 2025Enrolled332ConditionsCarcinoma, Pancreatic DuctalArmsMolecular Profiling
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lucy X MaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-1407-0715
Yifan WangResearch Institute of the McGill University Health Centre; Rosalind and Morris Goodman Cancer Institute, McGill University; Department of Surgery, McGill University, Montreal, QC, Canada.
Osvaldo Espin-GarciaDepartment of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Michael J AllenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Gun Ho JangPanCuRx Ontario Institute for Cancer Research, Toronto, ON, Canada.
Amy ZhangPanCuRx Ontario Institute for Cancer Research, Toronto, ON, Canada.
Anna DoddPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Stephanie RamotarPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Shawn HutchinsonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Mustapha TehfeCentre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Ravi RamjeesinghQEII Health Sciences Centre, Division of Medical Oncology, Dalhousie University, Halifax, NS, Canada.
James BiagiQueen's University, Kingston, ON, Canada.
Julie M WilsonPanCuRx Ontario Institute for Cancer Research, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-2510-962X
Faiyaz NottaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sandra E FischerDepartment of Pathology, University Health Network, Toronto, ON, Canada.
George ZogopoulosResearch Institute of the McGill University Health Centre; Rosalind and Morris Goodman Cancer Institute, McGill University; Department of Surgery, McGill University, Montreal, QC, Canada.
Steven GallingerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Robert C GrantPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Rama KhokhaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Nathan ChanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Barbara T GrünwaldPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jennifer J KnoxPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-3474-6647
Grainne M O'KanePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. grainne.o'kane@uhn.ca.ORCID http://orcid.org/0000-0002-8690-403X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic inflammatory scores may aid prognostication and patient selection for trials. We compared five scores in advanced pancreatic adenocarcinoma (PDAC).

methodsUnresectable/metastatic PDAC patients enrolled in the Comprehensive Molecular Characterisation of Advanced Pancreatic Ductal Adenocarcinoma for Better Treatment Selection trial (NCT02750657) were included. Patients had pre-treatment biopsies for whole genome and RNA sequencing. CD8 immunohistochemistry was available in a subset. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, Prognostic Nutritional Index, Gustave Roussy Immune Score (GRIm-S), and Memorial Sloan Kettering Prognostic Score (MPS) were calculated. Overall survival (OS) was estimated using Kaplan-Meier methods. Associations between inflammatory scores, clinical/genomic characteristics, and OS were analysed.

resultsWe analysed 263 patients. High-risk NLR, GRIm-S and MPS were poorly prognostic. The GRIm-S had the highest predictive ability: median OS 6.4 vs. 10 months for high risk vs. low-risk (P < 0.001); HR 2.26 (P < 0.001). ECOG ≥ 1, the basal-like subtype, and low-HRDetect were additional poor prognostic factors (P < 0.01). Inflammatory scores did not associate with RNA-based classifiers or homologous recombination repair deficiency genotypes. High-risk MPS (P = 0.04) and GRIm-S (P = 0.02) patients had lower median CD8 + tumour-infiltrating lymphocytes.

conclusionsInflammatory scores incorporating NLR have prognostic value in advanced PDAC. Understanding immunophenotypes of poor-risk patients and using these scores in trials will advance the field.

Indexed as

AdenocarcinomaPancreatic NeoplasmsHumansLymphocytesNeutrophilsPrognosisRetrospective Studies

Identifiers

PMID36927977
PMCPMC10147590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.